产品描述: | Epacadostat (INCB024360)是一种有效的选择性吲哚胺 2,3-双加氧酶(IDO1)抑制剂,IC50为 10 nM。它对IDO1的选择性高于其他相关酶如IDO2或TDO |
靶点: |
IDO1(immune cells):10 nM;IDO;Indoleamine2,3-Dioxygenase(IDO) |
体外研究: |
在IFN-γ-处理的人HeLa细胞中,INCB024360有效抑制犬尿素产生。INCB024360也会促进T和自然杀伤(NK)细胞的生长,增加IFN-γ产生,并减少转化为调节性T (T(reg))-样细胞 |
体内研究: |
INCB024360 (100 mg/kg, p.o.),通过IDO1抑制,在免疫活性小鼠中抑制kyn产生和肿瘤生长,但是在免疫缺陷小鼠中无效。 在负荷CT26结肠癌的小鼠中,INCB024360 (100 mg/kg, p.o.)通过减少犬尿素也会抑制表达IDO肿瘤的生长 |
细胞实验: |
Cell lines: Jurkat cells Concentrations: 50 μM Incubation Time: 72 h Method: Jurkat cells were incubated with serially diluted epacadostat for 72 h. Their viability was measured and analyzed as percentage of the non-treated control. |
动物实验: |
Animal Models: 负荷PAN02胰腺肿瘤的雌性C57BL/6或Balb/c nu/nu小鼠 Dosages: ~100 mg/kg,一天两次 Administration: p.o. |
参考文献: |
1. Liu X, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010, 115(17), 3520-3530. 2. Koblish HK, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther. 2010, 9(2), 489-498. 3. Richards T, et al. Cell based functional assays for IDO1 inhibitor screening and characterization. Oncotarget. 2018 Jul 20;9(56):30814-30820. |
溶解性: |
Soluble in DMSO、Ethanol |
保存条件: |
-20℃ |
配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
1 mM |
2.282 ml |
11.409 ml |
22.819 ml |
5 mM |
0.456 ml |
2.282 ml |
4.564 ml |
10 mM |
0.228 ml |
1.141 ml |
2.282 ml |
50 mM |
0.046 ml |
0.228 ml |
0.456 ml |
|
注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |